CLINICAL TRIALS PROFILE FOR VACTOSERTIB
✉ Email this page to a colleague
Clinical Trials for Vactosertib
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT02160106 ↗ | First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors | Completed | National OncoVenture | Phase 1 | The phase I dose escalation study will investigate the safety, tolerability, and pharmacokinetics of the TGF-β pathway inhibitor TEW 7197 in subjects with advanced, refractory solid tumors. |
NCT02160106 ↗ | First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors | Completed | MedPacto, Inc. | Phase 1 | The phase I dose escalation study will investigate the safety, tolerability, and pharmacokinetics of the TGF-β pathway inhibitor TEW 7197 in subjects with advanced, refractory solid tumors. |
NCT03074006 ↗ | Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDS | Completed | MedPacto, Inc. | Phase 1 | This is a prospective, open-label, multicenter, phase 1/2 study of TEW-7197 in patients with low and intermediate risk of myelodysplastic syndrome (MDS). |
NCT03143985 ↗ | Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma | Recruiting | Case Comprehensive Cancer Center | Phase 1 | The purpose of this study is to see if the study drug, called Vactosertib, is safe and determine what the best dose is to treat future patients when given in combination with pomalidomide (POM). The study will also look to see if it has any effect on multiple myeloma, when given in combination with POM. |
NCT03698825 ↗ | TEW-7197 With Paclitaxel for the Treatment of Metastatic Gastric Cancer | Active, not recruiting | MedPacto, Inc. | Phase 1/Phase 2 | This is an open-label, single arm study evaluating the safety and tolerability of TEW-7197 in combination with paclitaxel in metastatic gastric cancer patients. |
NCT03704675 ↗ | Effect of Food on the Pharmacokinetics of TEW-7197 in Healthy Subjects | Completed | MedPacto, Inc. | Phase 1 | Participants in this study will receive 200 milligram (mg) TEW-7197 taken at 7days apart. One dose will be given under fasting . The Other dose will be given with a high fat meal. The study will evaluate the effect of a high fat meal on how much of the drug gets into the blood stream. Side effects will be documented. This study will last approximately 2weeks not including screening. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Vactosertib
Condition Name
Clinical Trial Locations for Vactosertib
Trials by Country
Clinical Trial Progress for Vactosertib
Clinical Trial Phase
Clinical Trial Sponsors for Vactosertib
Sponsor Name